Researchers from Tokyo Metropolitan University have uncovered a potential breakthrough in Alzheimer’s disease (AD) treatment by targeting glucose metabolism in glial cells. Their study, conducted using fruit fly retinas, revealed that enhancing glucose processing in these cells alleviates inflammation and neurodegeneration linked to tau protein buildup, a hallmark of AD. The findings, published in Disease Models & Mechanisms, could pave the way for new therapies for neurodegenerative diseases.
The team, led by Professor Kanae Ando, focused on glial cells, which support neurons by clearing protein buildup and fueling brain activity through glucose metabolism. In AD patients, disrupted glucose metabolism in these cells coincides with tau protein accumulation, but the connection between the two remains unclear.
Using genetically modified fruit flies with tau buildup in their retinas, the researchers observed neurodegeneration and glial cell hyperactivity. Increasing the expression of a glucose transporter protein (GLUT) in glial cells successfully reduced inflammation and neurodegeneration, even though tau levels remained unchanged. This suggests that tau impairs glial glucose metabolism, exacerbating AD symptoms.
“Our findings highlight glial glucose metabolism as a critical lever in Alzheimer’s progression,” said Professor Ando. “Targeting this pathway could open doors to treatments not just for AD, but other neurodegenerative diseases like Parkinson’s.”
The study underscores the potential of restoring glial cell function to mitigate AD’s devastating effects. While further research is needed, this discovery offers hope for therapies that could slow or prevent neurodegeneration, significantly improving quality of life for millions worldwide.
Add comment